Abstract
Tuberculosis (TB) is one of the most important health concerns in the world, causing serious levels of morbidity and mortality, particularly in many developing countries. Unfortunately, the development of new anti-TB drugs with superior chemotherapeutic and prophylactic activity has been very slow. Thus, it is urgently necessary to develop novel kinds of antituberculosis drugs that exert their anti-Mycobacterium tuberculosis (MTB) activity through unique drug targets expressed by MTB organisms. At present, the drug targets of most current anti-TB drugs are primarily bacterial metabolic reactions and cell components that are indispensable to the growth and survival of MTB organisms in extracellular milieus, particularly in culture media. To develop novel and unique anti-TB drugs in the future, it is desirable to highlight the drug targets related to the bacterial ability to survive and replicate in host macrophages by escaping from a macrophage’s bacterial killing mechanism during infection inside such phagocytes. For this purpose, it is reasonable to focus our research efforts on mycobacterial virulence factors that cross-talk and interfere with signaling pathways of host macrophages, because such virulence factors will provide intracellular milieus favorable to intramacrophage survival and growth of MTB. In this chapter, based on such a viewpoint and strategy, the present status of worldwide research on novel potential drug targets related to Toll-like receptor in the MTB pathogen will be described
Keywords: Drug targets, macrophages, cytokines, mycobacteria, antituberculous drugs.
Current Pharmaceutical Design
Title:New Approaches to Tuberculosis - Novel Drugs Based on Drug Targets Related to Toll-Like Receptors in Macrophages
Volume: 20 Issue: 27
Author(s): Haruaki Tomioka
Affiliation:
Keywords: Drug targets, macrophages, cytokines, mycobacteria, antituberculous drugs.
Abstract: Tuberculosis (TB) is one of the most important health concerns in the world, causing serious levels of morbidity and mortality, particularly in many developing countries. Unfortunately, the development of new anti-TB drugs with superior chemotherapeutic and prophylactic activity has been very slow. Thus, it is urgently necessary to develop novel kinds of antituberculosis drugs that exert their anti-Mycobacterium tuberculosis (MTB) activity through unique drug targets expressed by MTB organisms. At present, the drug targets of most current anti-TB drugs are primarily bacterial metabolic reactions and cell components that are indispensable to the growth and survival of MTB organisms in extracellular milieus, particularly in culture media. To develop novel and unique anti-TB drugs in the future, it is desirable to highlight the drug targets related to the bacterial ability to survive and replicate in host macrophages by escaping from a macrophage’s bacterial killing mechanism during infection inside such phagocytes. For this purpose, it is reasonable to focus our research efforts on mycobacterial virulence factors that cross-talk and interfere with signaling pathways of host macrophages, because such virulence factors will provide intracellular milieus favorable to intramacrophage survival and growth of MTB. In this chapter, based on such a viewpoint and strategy, the present status of worldwide research on novel potential drug targets related to Toll-like receptor in the MTB pathogen will be described
Export Options
About this article
Cite this article as:
Tomioka Haruaki, New Approaches to Tuberculosis - Novel Drugs Based on Drug Targets Related to Toll-Like Receptors in Macrophages, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118163331
DOI https://dx.doi.org/10.2174/1381612819666131118163331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Mineral Deficiencies in Insulin Resistance and Obesity
Current Diabetes Reviews Autoimmune Diseases in Gastroenterology
Current Pharmaceutical Design Bioisosters of β-Lactams as Anti-Infectives
Current Medicinal Chemistry - Anti-Infective Agents Molecular Modeling Investigation of Some New 2-mercaptoimidazoles
Current Computer-Aided Drug Design Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Armed Imidazo [1,2-a] Pyrimidines (Pyridines): Evaluation of Antibacterial Activity
Letters in Drug Design & Discovery Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients Attending Chest Clinics in Osun-State, Nigeria
Current Pharmaceutical Biotechnology Why Do We Need New Drug Classes for HIV Treatment and Prevention?
Current Topics in Medicinal Chemistry Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine Synthesis of Imidazo[1,2-b]pyridazine Comprised Piperazine, Morpholine Derivatives as Potent Antimycobacterial Agents with In Vivo Locomotor Activity
Anti-Infective Agents Efflux Pump and its Inhibitors: Novel Targets to Combat Drug Resistance
Anti-Infective Agents Synthesis and SAR Studies of Urea and Thiourea Derivatives of Gly/Pro Conjugated to Piperazine Analogue as Potential AGE Inhibitors
Protein & Peptide Letters Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Ethambutol Induced Lichenoid Drug Eruption: A Case Report
Current Drug Safety Recent Advances and Future Perspectives of Triazole Analogs as Promising Antiviral Agents
Mini-Reviews in Medicinal Chemistry Are Topological Properties of Drug Targets Based on Protein-Protein Interaction Network Ready to Predict Potential Drug Targets?
Combinatorial Chemistry & High Throughput Screening SAR and Anti-Mycobacterial Activity of Quinolones and Triazoloquinolones: An Update
Anti-Infective Agents Molecular Modeling Databases: A New Way in the Search of Protein Targets for Drug Development
Current Bioinformatics Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy